Key facts
- Electra Therapeutics’s last known valuation is $479.0M (Oct 2025).
- It has raised $301.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($183.0M) in Oct 2025.
- Notable investors include RA Capital Management, OrbiMed, Blue Owl Capital, Cormorant Asset Management, EQT Life Sciences — 14 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Electra Therapeutics
Funding rounds
2 roundsAbout Electra Therapeutics
Operator of a biotechnology company intended for the treatment of immunological diseases and cancer. The company's lead product is a monoclonal antibody that targets a signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2018
- Employees
- 35
- Website
- electra-therapeutics.com/
- Ownership
- Privately Held (backing)
Electra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Electra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Electra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.